163 related articles for article (PubMed ID: 23836634)
1. Viral therapy of glioblastoma multiforme.
Whitley RJ; Markert JM
Proc Natl Acad Sci U S A; 2013 Jul; 110(29):11672-3. PubMed ID: 23836634
[No Abstract] [Full Text] [Related]
2. Immunovirotherapy for glioblastoma.
Ning J; Wakimoto H; Rabkin SD
Cell Cycle; 2014; 13(2):175-6. PubMed ID: 24241205
[No Abstract] [Full Text] [Related]
3. Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model.
Cheema TA; Wakimoto H; Fecci PE; Ning J; Kuroda T; Jeyaretna DS; Martuza RL; Rabkin SD
Proc Natl Acad Sci U S A; 2013 Jul; 110(29):12006-11. PubMed ID: 23754388
[TBL] [Abstract][Full Text] [Related]
4. Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model.
Alessandrini F; Menotti L; Avitabile E; Appolloni I; Ceresa D; Marubbi D; Campadelli-Fiume G; Malatesta P
Oncogene; 2019 Jun; 38(23):4467-4479. PubMed ID: 30755732
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma.
Saha D; Martuza RL; Rabkin SD
Immunotherapy; 2018 Jul; 10(9):779-786. PubMed ID: 30008259
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic viral therapy.
Inam Ur Rehma S; Haaris SM
J Pak Med Assoc; 2017 Apr; 67(4):658. PubMed ID: 28420939
[No Abstract] [Full Text] [Related]
7. RE: stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy.
Krause MN; Sancho-Martinez I; Izpisua Belmonte JC
J Natl Cancer Inst; 2015 Jan; 107(1):368. PubMed ID: 25473104
[No Abstract] [Full Text] [Related]
8. Response.
Martinez-Quintanilla J; Shah K
J Natl Cancer Inst; 2015 Jan; 107(1):370. PubMed ID: 25473105
[No Abstract] [Full Text] [Related]
9. How to get from here to there: tracking down invasive glioma cells.
Fine HA
J Natl Cancer Inst; 2014 Jun; 106(6):dju120. PubMed ID: 24838836
[No Abstract] [Full Text] [Related]
10. Viral Control of Glioblastoma.
Mihelson N; McGavern DB
Viruses; 2021 Jun; 13(7):. PubMed ID: 34209584
[TBL] [Abstract][Full Text] [Related]
11. Arming oHSV with ULBP3 drives abscopal immunity in lymphocyte-depleted glioblastoma.
Wirsching HG; Zhang H; Szulzewsky F; Arora S; Grandi P; Cimino PJ; Amankulor N; Campbell JS; McFerrin L; Pattwell SS; Ene C; Hicks A; Ball M; Yan J; Zhang J; Kumasaka D; Pierce RH; Weller M; Finer M; Quéva C; Glorioso JC; Houghton AM; Holland EC
JCI Insight; 2019 Jul; 4(13):. PubMed ID: 31292299
[TBL] [Abstract][Full Text] [Related]
12. Design and application of oncolytic HSV vectors for glioblastoma therapy.
Grandi P; Peruzzi P; Reinhart B; Cohen JB; Chiocca EA; Glorioso JC
Expert Rev Neurother; 2009 Apr; 9(4):505-17. PubMed ID: 19344302
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates.
Wollmann G; Ozduman K; van den Pol AN
Cancer J; 2012; 18(1):69-81. PubMed ID: 22290260
[TBL] [Abstract][Full Text] [Related]
14. Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models.
Saha D; Wakimoto H; Peters CW; Antoszczyk SJ; Rabkin SD; Martuza RL
Clin Cancer Res; 2018 Jul; 24(14):3409-3422. PubMed ID: 29599413
[No Abstract] [Full Text] [Related]
15. Emerging immunotherapies for glioblastoma.
Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
[TBL] [Abstract][Full Text] [Related]
16. Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus.
Uchida H; Marzulli M; Nakano K; Goins WF; Chan J; Hong CS; Mazzacurati L; Yoo JY; Haseley A; Nakashima H; Baek H; Kwon H; Kumagai I; Kuroki M; Kaur B; Chiocca EA; Grandi P; Cohen JB; Glorioso JC
Mol Ther; 2013 Mar; 21(3):561-9. PubMed ID: 23070115
[TBL] [Abstract][Full Text] [Related]
17. Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts.
Cheema TA; Kanai R; Kim GW; Wakimoto H; Passer B; Rabkin SD; Martuza RL
Clin Cancer Res; 2011 Dec; 17(23):7383-93. PubMed ID: 21976549
[TBL] [Abstract][Full Text] [Related]
18. Immune and viral therapies for malignant primary brain tumors.
Gardeck AM; Sheehan J; Low WC
Expert Opin Biol Ther; 2017 Apr; 17(4):457-474. PubMed ID: 28274139
[TBL] [Abstract][Full Text] [Related]
19. Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy.
Gromeier M; Brown MC; Zhang G; Lin X; Chen Y; Wei Z; Beaubier N; Yan H; He Y; Desjardins A; Herndon JE; Varn FS; Verhaak RG; Zhao J; Bolognesi DP; Friedman AH; Friedman HS; McSherry F; Muscat AM; Lipp ES; Nair SK; Khasraw M; Peters KB; Randazzo D; Sampson JH; McLendon RE; Bigner DD; Ashley DM
Nat Commun; 2021 Jan; 12(1):352. PubMed ID: 33441554
[TBL] [Abstract][Full Text] [Related]
20. Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy.
Duebgen M; Martinez-Quintanilla J; Tamura K; Hingtgen S; Redjal N; Wakimoto H; Shah K
J Natl Cancer Inst; 2014 Jun; 106(6):dju090. PubMed ID: 24838834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
